Vascular endothelial growth inhibitor, expression in human prostate cancer tissue and the impact on adhesion and migration of prostate cancer cells in vitro

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1473-1480

  Zhang, Ning ^a,b   Sanders, Andrew J ^a   Ye, Lin ^a   Kynaston, Howard G ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cell adhesion; Cell migration; Prostate cancer; Vascular endothelial growth inhibitor

Indexed keywords

VASCULOTROPIN INHIBITOR; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; CELL MOTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL ADHESION; CELL MOVEMENT; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 73949109485     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000466     Document Type: Article

References (27)

1. Oliver SE, Gunnell D and Donovan JL: Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355: 1788-1789, 2000.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
3. Tan KB, Harrop J, Reddy M, et al: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46, 1997.
4. Zhai Y, Ni J, Jiang GW, et al: VEGI, a novel cytokine of the tumour necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189, 1999.
5. Zhai Y, Yu J, Iruela-Arispe L, et al: Inhibition of angiogenesis and breast cancer xenograft tumour growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82: 131-136, 1999.
6. Yao JJ, Zhang M, Miao XH, et al: Isoform of vascular endothelial cell growth inhibitor (VEGI72-251) increases interleukin-2 production by activation of T lymphocytes. Acta Biochim Biophys Sin 38: 249-253, 2006.
7. Jin T, Guo F, Kim S, et al: X-ray crystal structure of TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun 364: 1-6, 2007.
8. Chew LJ, Pan H, Yu J, et al: A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16: 742-744, 2002.
9. Park SS, Lillehoj HS, Hong YH, et al: Functional characterization of tumour necrosis factor superfamily 15 (TNFSF15) induced by lipopolysaccharides and Eimeria infection. Dev Comp Immunol 31: 934-944, 2007.
10. Xiao Q, Hsu CY, Chen H, et al: Characterization of cisregulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388: 913-920, 2005.
11. Hou W, Medynski D, Wu S, et al: VEGI-192, a new isoform of TNFSF15, specifically eliminates tumour vascular endothelial cells and suppresses tumour growth. Clin Cancer Res 11: 5595-5602, 2005.
12. Parr C, Gan CH, Watkins G, et al: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81, 2006.
13. Yang CR, Hsieh SL, Teng CM, et al: Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumour necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64: 1122-1129, 2004.
14. Jiang WG, Davies G, Martin TA, et al: Targeting matrilysin and its impact on tumour growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 11: 6012-6019, 2005.
15. Jiang WG, Davies G, Martin TA, et al: Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 17: 583-590, 2006.
16. Kang H, Mansel RE and Jiang WG: Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int J Oncol 26: 1429-1434, 2005.
17. Jiang WG, Hiscox S, Hallett MB, et al: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 71: 744-752, 1995.
18. Jiang WG, Hiscox S, Singhrao SK, Puntis MCA, Nakamura T, Mansel RE and Hallett MB: Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor (HGF/SF). Biochem Biophys Res Commun 217: 1062-1069, 1995.
19. Jiang WG, Martin TA, Lewis-Russell JM, et al: Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7: 71, 2008.
20. Migone TS, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
21. Zhang N, Sanders AJ, Ye L and Jiang WG: Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med 24: 3-8, 2009.
22. Yue T, Ni J, Romanic AM, et al: TL1, a novel tumour necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stressactivated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 274: 1479-1486, 1999.
23. Haridas V, Shrivastava A, Su J, et al: VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun Nterminal kinase and modulates cell growth. Oncogene 18: 6496-6504, 1999.
24. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395, 2000.
25. Prehn JL, Thomas LS, Landers CJ, et al: The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178: 4033-4038, 2007.
26. Cassatella MA, Pereira-da-Silva G, Tinazzi I, et al: Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 178: 7325-7333, 2007.
27. Bamias G, Mishina M, Nyce M, et al: Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA 103: 8441-8446, 2006.